Sobottka S B, Berger M R, Eibl H
German Cancer Research Center, Institute of Toxicology and Chemotherapy, Heidelberg.
Int J Cancer. 1993 Feb 1;53(3):418-25. doi: 10.1002/ijc.2910530312.
This study was carried out to investigate whether structure-activity relationships of alkylphosphocholines, a new group of anti-neoplastic agents, which had been detected in methylnitrosourea(MNU)-induced rat mammary carcinoma, can be transferred to in vitro systems. Therefore, the anti-neoplastic activity of 4 alkylphosphocholines (APCs) was compared in 6 tumor cell lines in vitro and in MNU-induced rat mammary carcinoma in vivo. The in vitro system consisted of 2 rat mammary-carcinoma-derived cell lines (1/C2 and 1/C32), as well as 2 human mammary-gland (MDA-MB-231 and MCF-7)- and gastrointestinal tract (HT-29 and KB)-derived tumor cell lines. As assessed by both cell counting and MTT-assay, the ranking of concentrations effecting 50% growth inhibition (IC50) was parallel in all cell lines for octadecylphosphocholine (18:0-PC), octadecenyl-(trans-9.10)-phosphocholine (t-18:1-PC) and octadecenyl-(cis-9.10)-phosphocholine (c-18:1-PC). Only hexadecylphosphocholine (16:0-PC) differed in its activity, being least active in 1/C2, 1/C32 and MDA-MB-231 cells, moderately active in KB and MCF-7 cells, and most active in HT-29 cells. The IC50 concentrations of APCs in the 2 rat mammary carcinoma cell lines significantly correlated with dosages effecting a 50% tumor growth delay in vivo. Remarkably, the 2 gastrointestinal cell lines were more sensitive to APC exposure than the mammary-carcinoma cell lines. In all cell lines except KB cells, growth-stimulation effects were seen in the concentration range preceding the anti-proliferative activity; in vivo, however, no accelerated cancer growth was observed. The in vitro system failed to describe the superior therapeutic ratio of c-18:1-PC, as assessed in vivo, because it does not take the relative sensitivity of tumor vs. normal cells into account. Complementary in vivo trials are therefore indispensable for a final evaluation. Comparison of the 2 in vitro assays shows good agreement of the interrelationship of IC50 values, those obtained by MTT assay being on average 25% higher than those obtained from cell counting.
本研究旨在调查在甲基亚硝基脲(MNU)诱导的大鼠乳腺癌中检测到的一类新型抗肿瘤药物烷基磷胆碱的构效关系是否能转移至体外系统。因此,比较了4种烷基磷胆碱(APCs)在6种肿瘤细胞系中的体外抗肿瘤活性以及在MNU诱导的大鼠乳腺癌中的体内抗肿瘤活性。体外系统包括2种源自大鼠乳腺癌的细胞系(1/C2和1/C32),以及2种源自人乳腺(MDA-MB-231和MCF-7)和胃肠道(HT-29和KB)的肿瘤细胞系。通过细胞计数和MTT法评估,在所有细胞系中,对十八烷基磷胆碱(18:0-PC)、十八碳烯基-(反式-9,10)-磷胆碱(t-18:1-PC)和十八碳烯基-(顺式-9,10)-磷胆碱(c-18:1-PC)产生50%生长抑制(IC50)的浓度排名是平行的。只有十六烷基磷胆碱(16:0-PC)的活性不同,在1/C2、1/C32和MDA-MB-231细胞中活性最低,在KB和MCF-7细胞中活性中等,在HT-29细胞中活性最高。APCs在2种大鼠乳腺癌细胞系中的IC50浓度与体内产生50%肿瘤生长延迟的剂量显著相关。值得注意的是,2种胃肠道细胞系比乳腺癌细胞系对APC暴露更敏感。在除KB细胞外的所有细胞系中,在抗增殖活性之前的浓度范围内观察到生长刺激作用;然而,在体内未观察到癌症生长加速。体外系统未能描述如在体内评估的c-18:1-PC的优异治疗指数,因为它没有考虑肿瘤细胞与正常细胞的相对敏感性。因此,补充的体内试验对于最终评估是必不可少的。两种体外试验的比较显示IC50值的相互关系具有良好的一致性,通过MTT法获得的值平均比通过细胞计数获得的值高25%。